15 terminated. 15 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Terminated 15 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Nausea: new trials by email Literature Review of Nausea trials Research Report on Nausea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention BHV-3500 (zavegepant), Placebo - Migraine | Phase 2 / Phase 3 | Terminated | Pfizer | 1753 | 2021-03-26 | 2025-03-27 |
| Validating the Effect og Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum Mirtazapine, Ondansetron, Placebo - Hyperemesis Gravidarum, Nausea Gravidarum | Phase 2 | Terminated | Nordsjaellands Hospital | 58 | 2019-03-01 | 2023-01-30 |
| Efficacy of Extended-release, Once Daily Tramadol for Post Operative Analgesia in Shoulder Arthroscopy tramadol, Placebo - Pain, Vertigo | Phase 2 | Terminated | Centre hospitalier de l'Université de Montréal (CHUM) | 100 | 2013-06-01 | 2020-07-24 |
| Dexamethasone for the Treatment of Established Postoperative Nausea and Vomiting Placebo, Dexamethasone 3 mg, Dexamethasone 6 mg - Postoperative Nausea and Vomiting, Vomiting | Phase 2 | Terminated | University Hospital, Geneva | 256 | 2012-09-03 | 2019-12-10 |
| Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030) Fosaprepitant dimeglumine, 5-HT3 RA, Dexamethasone - Nausea, Vomiting | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 111 | 2011-10-25 | 2018-08-27 |
| Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study Aprepitant, Palliative radiation therapy, Granisetron - Nausea, Vomiting | Phase 2 | Terminated | Sunnybrook Health Sciences Centre | 19 | 2011-01-01 | 2019-10-09 |
| Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients Palonosetron - Nausea, Vomiting | Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 3 | 2010-11-01 | 2015-12-04 |
| Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents Oral Aprepitant, Aprepitant - Nausea, Vomiting | Phase 2 | Terminated | The Hospital for Sick Children | 4 | 2010-10-01 | 2017-04-19 |
| Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer palonosetron hydrochloride, placebo - Anal Cancer, Carcinoma of the Appendix | Phase 2 | Terminated | Alliance for Clinical Trials in Oncology | 7 | 2009-09-01 | 2017-11-24 |
| Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy fosaprepitant dimeglumine, cisplatin, palonosetron hydrochloride - Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx | Phase 2 | Terminated | University of Washington | 6 | 2009-02-01 | 2017-05-18 |
| Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy fosaprepitant dimeglumine, systemic chemotherapy, survey administration - Breakthrough Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Terminated | OHSU Knight Cancer Institute | 34 | 2008-08-01 | 2017-05-09 |
| Study of Nicotine for the Prevention of PONV Nicotine - Postoperative Nausea and Vomiting | Phase 2 | Terminated | University Hospital, Geneva | 200 | 2007-10-01 | 2009-09-29 |
| Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy Decadron®, Benadryl®, Ativan® - Nausea, Vomiting | Phase 2 | Terminated | University of South Florida | 7 | 2007-10-01 | 2014-07-25 |
| Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy inhaled delta-8-THC 300mcg or 600mcg per dose - Cancer | Phase 2 | Terminated | Rafa Laboratories | 6 | 2005-11-01 | 2020-12-23 |
| 12 Weeks Treatment With DDP225 or Placebo in Patients With Chronic Functional Vomiting DDP225 - Vomiting | Phase 2 | Terminated | Dynogen Pharmaceuticals | 30 | 2005-11-01 | 2007-10-12 |
Vomiting (12) · Postoperative Nausea and Vomiting (2) · Anus Neoplasms (1) · Appendiceal Neoplasms (1) · Bile Duct Neoplasms (1) · Carcinoma, Hepatocellular (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Gallbladder Neoplasms (1) · Hyperacusis (1) · Hyperemesis Gravidarum (1) · Liver Neoplasms (1) · Migraine Disorders (1) · Neoplasms (1)
Pathological Conditions, Signs and Symptoms (15) · Signs and Symptoms (15) · Signs and Symptoms, Digestive (15) · Carcinoma (2) · Ear Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Nervous System Diseases (2) · Neurologic Manifestations (2) · Otorhinolaryngologic Diseases (2) · Pathologic Processes (2) · Postoperative Complications (2) · Adenocarcinoma (1)
Dexamethasone (4) · Aprepitant (3) · Ondansetron (3) · Palonosetron (3) · fosaprepitant (3) · Calcium Dobesilate (2) · Adrenal Cortex Hormones (1) · Cisplatin (1) · Diphenhydramine (1) · Granisetron (1) · Lorazepam (1) · Mirtazapine (1) · Neoadjuvant Therapy (1) · Nicotine (1) · Radiotherapy (1)
University Hospital, Geneva (2) · Alliance for Clinical Trials in Oncology (1) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Dynogen Pharmaceuticals (1) · Merck Sharp & Dohme LLC (1) · Nordsjaellands Hospital (1) · OHSU Knight Cancer Institute (1) · Pfizer (1) · Rafa Laboratories (1) · Sunnybrook Health Sciences Centre (1) · The Hospital for Sick Children (1) · University of Michigan Rogel Cancer Center (1) · University of South Florida (1) · University of Washington (1)
United States (7) · Canada (3) · Switzerland (2) · Denmark (1) · Israel (1) · Puerto Rico (1)
Anne Ostenfeld, MD (1) · Christoph Czarnetzki, MD (1) · Daniel Bertrand, PhD (1) · Edward Chow, MBBS PhD FRCPC (1) · Haydar Frangoul, MD (1) · Jean-Denis Roy, Doctor (1) · Joseph Bubalo, PharmD, BCPS, BCOP (1) · Keith Eaton (1) · Lee Dupuis, RPh, MScPhm, ACPR, FCSH (1) · Michele Yvette Halyard, MD (1) · Nathan Cherny, MD (1)
PMID 32209630, PMID 34799501, PMID 41478546, PMID 42645743
P30CA069533 (1), U10CA081920 (1)